Editor—Older patients with current or previous SARS-CoV-2 infection (COVID-19) have been undergoing surgical interventions at an increasing rate during the COVID-19 pandemic and face a high risk of postoperative complications. Most older patients are expected to recover from acute postoperative complications, including most pulmonary and renal complications and delirium. Recently, a national database study on hip fracture characteristics and outcomes during the COVID-19 pandemic in the USA showed that older patients with hip fracture and concomitant COVID-19 experienced significantly higher rates of acute postoperative complications, especially pulmonary complications (22.9%).1 However, long-term neurological sequelae, such as perioperative neurocognitive disorders (PNDs), commonly occurring in older patients after major noncardiac surgery (incidence as high as 40%),2 , 3 have received relatively little attention.
PNDs that encompass acute postoperative delirium and longer-lasting postoperative cognitive dysfunction are age-related neurological disorders and are associated with dementia.4 Older patients with a PND have a significantly increased mortality 3 months after surgery and are at risk for a higher rate of disability, leading to loss of employment, which may lead to a greater reliance on social security.5 Interestingly, the enhanced expression of angiotensin-converting enzyme-2 (ACE-2) receptors in the CNS of patients with dementia may make them more susceptible to COVID-19 (Fig. 1 ).6 , 7 Clinical studies have identified advanced age, major surgery, low educational level, history of alcohol or opioid use, anticholinergic medication, and pre-existing cognitive impairment as important risk factors for PND.3 , 8 The COVID-19 pandemic has significantly affected the epidemiological characteristics of many diseases, and COVID-19 must be considered a potential risk factor for acute or chronic neurological complications because the causative virus, SARS-CoV-2, is more invasive in the CNS than other coronaviruses.9 , 10 Acute neurological symptoms associated with COVID-19, including confusion, headache, hypogeusia, hyposmia, and seizures, provide evidence of direct invasion by SARS-CoV-2 into the CNS. Most patients with COVID-19 fully resolve from these acute symptoms after clinical recovery.7 However, a small observational study showed that 33% of patients with severe COVID-19 experienced cognitive and motor dysfunction, including inattention, disorientation, and poorly organised movements in response to command, even after hospital discharge.11 Long-term neurological disorders have been observed in non-critical patients with COVID-19 as well, although results are yet to be completed.12 Moreover, COVID-19 may promote the initiation and progression of age-related progressive neurodegenerative conditions, such as Alzheimer's disease (AD). Preliminary observations have revealed that COVID-19 causes worsening of behavioural symptoms and potential gradual aggravation of the underlying AD neuropathologies and related dementia, which may take months or years to detect.13, 14, 15 Support for a relationship between age-related neurodegenerative conditions and COVID-19 has yet to be reported because of the recent origin of the pandemic.
Fig 1.
Mechanism of neuroinvasion by SARS-CoV-2 and the potential association between SARS-CoV-2 infection, anaesthesia and surgery, and PND in cognitive impairment. Neuroinvasion by SARS-CoV-2 occurs through retrograde axonal transport along the olfactory bulb or disrupted blood–brain barrier. SARS-CoV-2 infection combined with anaesthesia and surgery may lead to significant neuroinflammation, excess mtROS, and amyloid-beta accumulation that can cause hippocampus injury. Furthermore, PND may lead to enhanced ACE-2 expression in the hippocampus, making it more susceptible to SARS-CoV-2 infection. ACE-2, angiotensin-converting enzyme-2; IL-1β, interleukin-1β; IL-6, interleukin-6; mtDNA, mitochondrial DNA; mtROS, mitochondrial reactive oxygen species; PND, perioperative neurocognitive disorder; TNF-α, tumour necrosis factor-α.
Anaesthesia and surgery can disrupt the integrity of the blood–brain barrier (BBB) and facilitate migration of peripheral innate immune molecules into the hippocampus, and SARS-CoV-2 infection may accelerate this process.16 , 17 Neurotoxicity via ACE-2 receptors in the hippocampus can be caused by SARS-CoV-2 via its access to the CNS through retrograde axonal transport along the olfactory bulb or disrupted BBB (Fig. 1).7 , 9 SARS-CoV-2-mediated immune responses can also play a critical role in cognitive impairment through indirect CNS involvement. Furthermore, the molecular mechanisms, including significant neuroinflammation, mitochondrial oxidative stress, and accumulation of amyloid beta (Aβ), of SARS-CoV-2-induced cognitive disorders are similar to those of PNDs (Fig. 1).7 , 8 Surgical trauma can trigger complement signalling activation in the CNS and subsequently activate microglia via CD11b signalling, which further increases SARS-CoV-2-mediated neuroinflammation.9 , 18 A recent editorial suggested a correlation between PND and cognitive disorders associated with SARS-CoV-2 because of their overlapping inflammatory response to injury.12 The authors stated that it may be beneficial to alleviate long-term neurological consequences of COVID-19 by implementing preventive interventions or treatments before surgery and anaesthesia, which could improve pre-existing poor cognitive and functional outcomes for patients with COVID-19.
Increasing evidence suggests that mitochondrial dysfunction is involved in both PND and COVID-19.8 , 19 SARS-CoV-2 can enter cells via the ACE-2 receptor and affect mitochondria, causing increased fusion and excess production of reactive oxygen species, thereby damaging mitochondrial DNA and accelerating CNS oxidative stress.19 Additionally, reports have suggested a critical role of Aβ accumulation in the brain in PND.20 SARS-CoV-2 neuroinvasion could promote endothelial dysfunction and loss of pericytes (disrupted BBB), which can impair Aβ clearance and lead to excess Aβ generation in the hippocampus.7 , 16 SARS-CoV-2 infection could directly induce Aβ generation in the CNS as part of the immune response; however, this hypothesis needs to be tested further.7
Taken together, COVID-19 may potentially lead to an accelerated cognitive decline associated with anaesthesia and surgical stress through independent and synergistic mechanisms. COVID-19 soon could be recognised as a long-term risk factor for accelerated onset or deterioration of PND in the ageing population undergoing surgery. Future clinical research needs to consider COVID-19 as a potential risk factor for PND in the post-COVID-19 era. Long-term prospective longitudinal studies in older patients undergoing surgery and anaesthesia with concomitant or previous COVID-19 diagnosis should be designed to determine the effect of COVID-19 on the pathological progression of PND and other age-related dementias.
Declarations of interest
The authors declare that they have no conflicts of interest.
Funding
Natural Science Foundation of Shandong Province (ZR2020QH291 and ZR2020MH126); Key Research and Development Plan of Shandong Province (2019GSF108228); Qingdao Key Health Discipline Development Fund (2019); Qingdao Outstanding Health Professional Development Fund (2019); Scientific Research Foundation of Qilu Hospital of Shandong University (Qingdao), China (QDKY2018QN12 and QDKY2019YC06).
References
- 1.Zhong H., Poeran J., Liu J., Wilson L.A., Memtsoudis S.G. Hip fracture characteristics and outcomes during COVID-19: a large retrospective national database review. Br J Anaesth. 2021;127:15–22. doi: 10.1016/j.bja.2021.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Wiles M.D. Should cognitive impairment be an exclusion criterion for hip fracture studies? Br J Anaesth. 2013;111:514. doi: 10.1093/bja/aet273. [DOI] [PubMed] [Google Scholar]
- 3.Monk T.G., Weldon B.C., Garvan C.W., et al. Predictors of cognitive dysfunction after major noncardiac surgery. Anesthesiology. 2008;108:18–30. doi: 10.1097/01.anes.0000296071.19434.1e. [DOI] [PubMed] [Google Scholar]
- 4.Subramaniyan S., Terrando N. Neuroinflammation and perioperative neurocognitive disorders. Anesth Analg. 2019;128:781–788. doi: 10.1213/ANE.0000000000004053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Steinmetz J., Christensen K.B., Lund T., Lohse N., Rasmussen L.S., ISPOCD Group Long-term consequences of postoperative cognitive dysfunction. Anesthesiology. 2009;110:548–555. doi: 10.1097/ALN.0b013e318195b569. [DOI] [PubMed] [Google Scholar]
- 6.Ding Q., Shults N.V., Harris B.T., Suzuki Y.J. Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer’s disease brain. bioRxiv. October 8 2020 doi: 10.1101/2020.10.08.331157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ciaccio M., Lo Sasso B., Scazzone C., et al. COVID-19 and Alzheimer’s disease. Brain Sci. 2021;11:305. doi: 10.3390/brainsci11030305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Skvarc D.R., Berk M., Byrne L.K., et al. Post-operative cognitive dysfunction: an exploration of the inflammatory hypothesis and novel therapies. Neurosci Biobehav Rev. 2018;84:116–133. doi: 10.1016/j.neubiorev.2017.11.011. [DOI] [PubMed] [Google Scholar]
- 9.Amruta N., Chastain W.H., Paz M., et al. SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine Growth Factor Rev. 2021;58:1–15. doi: 10.1016/j.cytogfr.2021.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hosseini N., Nadjafi S., Ashtary B. Overview of COVID-19 and neurological complications. Rev Neurosci. February 15 2021 doi: 10.1515/revneuro-2020-0116. [DOI] [PubMed] [Google Scholar]
- 11.Helms J., Kremer S., Merdji H., et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268–2270. doi: 10.1056/NEJMc2008597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Baker H.A., Safavynia S.A., Evered L.A. The ‘third wave’: impending cognitive and functional decline in COVID-19 survivors. Br J Anaesth. 2021;126:44–47. doi: 10.1016/j.bja.2020.09.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Cohen G., Russo M.J., Campos J.A., Allegri R.F. COVID-19 epidemic in Argentina: worsening of behavioral symptoms in elderly subjects with dementia living in the community. Front Psychiatry. 2020;11:866. doi: 10.3389/fpsyt.2020.00866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Daugherty A.M., Chopra T., Korzeniewski S.J., Levy P. COVID-19 as a risk factor for Alzheimer’s disease and related dementia: a perspective from Detroit, MI. Psychiatry Res. 2020;294:113557. doi: 10.1016/j.psychres.2020.113557. [DOI] [PubMed] [Google Scholar]
- 15.Hascup E.R., Hascup K.N. Does SARS-CoV-2 infection cause chronic neurological complications? GeroScience. 2020;42:1083–1087. doi: 10.1007/s11357-020-00207-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Baig A.M., Khaleeq A., Ali U., Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11:995–998. doi: 10.1021/acschemneuro.0c00122. [DOI] [PubMed] [Google Scholar]
- 17.Eckenhoff R.G., Maze M., Xie Z., et al. Perioperative neurocognitive disorder: state of the preclinical science. Anesthesiology. 2020;132:55–68. doi: 10.1097/ALN.0000000000002956. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yang T., Velagapudi R., Terrando N. Neuroinflammation after surgery: from mechanisms to therapeutic targets. Nat Immunol. 2020;21:1319–1326. doi: 10.1038/s41590-020-00812-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Ganji R., Reddy P.H. Impact of COVID-19 on mitochondrial-based immunity in aging and age-related diseases. Front Aging Neurosci. 2020;12:614650. doi: 10.3389/fnagi.2020.614650. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Xie Z., McAuliffe S., Swain C.A., et al. Cerebrospinal fluid Aβ to tau ratio and postoperative cognitive change. Ann Surg. 2013;258:364–369. doi: 10.1097/SLA.0b013e318298b077. [DOI] [PMC free article] [PubMed] [Google Scholar]

